Table 2 Recent agents targeting HER2 in different cancer

Indication

HER2 overexpressing (Adjuvant, neoadjuvant and Late first-line therapy) [92] (FDA/EMA Approved)

HER2-overexpressing metastatic gastric/Gastroesophageal junction adenocarcinoma (Adjuvant, first - and second-line therapy) [93] (FDA/EMA Approved)

_

_

_

_

Ongoing clinical trials (stage)

NCT02625441 (III)

NCT02625441(III)

NCT03084939(III)

NCT03615326 (III)

NCT04661150 (II)

NCT04888663 (II)

NCT04644237 (II)

NCT03845270(II)

NCT04579380(II)

NCT02091141 (II)

NCT05786716 (II/III)

NCT02091141(II)

NCT04579380(II)

NCT05749900(I/II)

NCT03457896 (II)

NCT03043313 (II)

NCT05786716(II/III)

Pertuzumab

Indication

HER2-overexpressing (Adjuvant, neoadjuvant and Late first-line therapy) [94]

(FDA/EMA Approved)

_

_

_

_

_

Ongoing clinical trials (stage)

NCT02625441 (III)

NCT03493854(III)

NCT01358877(III)

NCT01461057 (III)

NCT02581462 (II/III)

NCT02507375(I)

NCT00855894 (II)

NCT00063154 (II)

NCT02091141 (II)

NCT05786716 (III)

NCT02465060(II)

NCT02091141(II)

NCT05786716(II/III)

NCT03365882(II)

NCT02465060(II)

NCT01376505(I)

Inetetamab

Indication

HER2-overexpressing (Late first-line therapy, second and third line therapy) [95]

(NMPA Approved)

_

_

_

_

_

Ongoing clinical trials (stage)

NCT04941885(II)

NCT04681911(II)

NCT05764941(real-word study)

_

NCT05016544(I)

_

_

_

Margetuximab

Indication

HER2-overexpressing breast cancer(Third-line therapy) [96](FDA Approved)

_

_

_

_

_

Ongoing clinical trials

(stage)

NCT04425018(II)

NCT04262804(II)

NCT04425018(II)

NCT04082364(II)

NCT01148849(I)

NCT03219268(I)

_

_

_

ADC

T-DM1

Indication

HER2-overexpressing breast cancer(Adjuvant, neoadjuvant and Second-line therapy) [97](FDA/EMA Approved)

_

_

_

_

_

Ongoing clinical trials

(stage)

NCT03529110 (III)

NCT03084939(III)

NCT04740918(III)

NCT02465060(II)

NCT04042701(I)

NCT05650879 (I)

NCT02314481(II)

NCT02465060(II)

NCT02675829(II)

NCT02465060(II)

NCT02465060(II)

NCT05578287 (II)

NCT03225937 (II)

T-DXd

Indication

HER2-overexpressin(Adjuvant, neoadjuvant and Late second-line therapy) [98] HER2-lowexpression (Adjuvant and second-line therapy) [99]

(FDA/EMA Approved)

HER2-overexpressing gastric cancer/ Gastroesophageal junction carcinoma (Second-line therapy) [100](FDA/EMA Approved)

HER2-positive metastatic (Adjuvant) [101]

(FDA Approved)

_

_

_

Ongoing clinical trials

(stage)

NCT04622319 (III)

NCT04784715 (III)

NCT04494425 (III)

NCT04639219 (II)

NCT04989816 (II)

NCT04379596 (II)

NCT04686305(I)

NCT05246514(II)

NCT05048797 (III)

NCT04482309(II)

NCT04644068(I/II

NCT04482309(II)

NCT04644068(I/II)

NCT04744831(II)

NCT04639219(II)

NCT04644068(I/II)

RC-48

Indication

_

HER2-overexpressing metastatic gastric/ Gastroesophageal junction adenocarcinoma(Second and third line therapy therapy) (NMPA Approved)

_

HER2-overexpression urothelial carcinoma(Second-line therapy) (NMPA Approved)

_

Ongoing clinical trials (stage)

NCT03052634(I/ II)

NCT05134519 (II)

NCT05331326 (II)

NCT05514158(I)

NCT04714190 (III)

NCT04311034(Ib)

NCT05745740(I)

NCT05356351(II)

NCT05297552(II)

NCT05016973(II)

NCT04329429(II)

NCT05417230(II)

NCT05785325(II)

NCT05578287(II)

TKI

Neratinib

Indication

HER2 -overexpressing (Adjuvant ,Second - and third-line therapy) [102]

(FDA/EMA Approved)

_

_

_

_

_

Ongoing clinical trials

(stage)

NCT05760612 (III)

NCT04965064(II)

NCT05252988(II)

NCT05512182(II)

NCT05274048(I)

NCT01827267(II)

_

NCT03919292(I)

NCT01960023(II)

NCT03457896(II)

NCT03919292(I)

Lapatinib

Indication

HER2 -overexpressing breast cancer (Second - and third-line therapy) [103]

(FDA/EMA Approved)

_

_

_

_

_

Ongoing clinical trials

(stage)

NCT05122494 (III)

NCT03084939(III)

NCT00770809(III)

NCT00680901 (III)

NCT02015169(II)

NCT00313599(I)

NCT01306045(II)

NCT03845270(II)

NCT01184482(I)

NCT00313599(I)

NCT00623064(I)

NCT01184482(I)

NCT04831528(II)

NCT00044343(II)

NCT01184482(I)

Tucatinib

Indication

HER2 -overexpressing (Adjuvant, neoadjuvant, Second - and third-line therapy) [104]

(FDA/EMA Approved)

_

_

_

_

_

Ongoing clinical trials (stage)

NCT03054363 (I/ II)

NCT02614794(II)

NCT05132582(III)

NCT05190445(II)

NCT05382364(I)

NCT02892123(I)

NCT04579380(II)

NCT02892123(I)

_

NCT04579380(II)

NCT05253651(III)

NCT03043313 (II)

NCT04430738 (II)

Pyrotinib

Indication

HER2 -overexpressing (Adjuvant, neoadjuvant and Late first-line therapy) [105] (NMPA Approved)

_

_

_

_

_

Ongoing clinical trials (stage)

NCT04646759(III)

NCT04254263(III)

NCT02973737(III)

NCT05070598(II)

NCT05111444(II)

NCT02500199(I)

NCT04144569(II)

NCT04447118(III)

NCT05751018(III)

NCT05318339(II)

NCT04571710(II)

NCT05350917(II)